Back

MAIT Cells Modulate Innate Immune Cells and Inhibit Colon Cancer Growth

Cheng, O. J.; Lebish, E. J.; Jensen, O.; Jacenik, D.; Trivedi, S.; Cacioppo, J.; Aube, J.; Beswick, E. J.; Leung, D. T.

2024-01-20 cancer biology
10.1101/2024.01.16.575894 bioRxiv
Show abstract

Mucosal-associated invariant T (MAIT) cells are innate-like T cells that can be activated by microbial antigens and cytokines and are abundant in mucosal tissues including the colon. MAIT cells have cytotoxic and pro-inflammatory functions and have potentials for use as adoptive cell therapy. However, studies into their anti-cancer activity, including their role in colon cancer, are limited. Using an animal model of colon cancer, we show that peritumoral injection of in vivo-expanded MAIT cells into RAG1-/- mice with MC38-derived tumors inhibits tumor growth compared to control. Multiplex cytokine analyses show that tumors from the MAIT cell-treated group have higher expression of markers for eosinophil-activating cytokines, suggesting an association between eosinophil recruitment and tumor inhibition. In a human peripheral leukocyte co-culture model, we show that leukocytes stimulated with MAIT ligand show an increase in eotaxin-1 production and activation of eosinophils, associated with increased cancer cell killing. In conclusion, we show that MAIT cells have a protective role in a murine colon cancer model, associated with modulation of the immune response to cancer, potentially involving eosinophil-associated mechanisms. Our results highlight the potential of MAIT cells for non-donor restricted colon cancer immunotherapy. Brief summaryIn models of colon cancer, MAIT cells have anti-tumor activity, associated with increased production of proinflammatory and eosinophil-modulating cytokines.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
15.2%
2
OncoImmunology
22 papers in training set
Top 0.1%
10.4%
3
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.1%
7.4%
4
Frontiers in Immunology
586 papers in training set
Top 1%
5.0%
5
PLOS ONE
4510 papers in training set
Top 34%
4.3%
6
Scientific Reports
3102 papers in training set
Top 34%
3.7%
7
Frontiers in Oncology
95 papers in training set
Top 1%
3.2%
8
Immunology
29 papers in training set
Top 0.3%
2.2%
50% of probability mass above
9
International Journal of Molecular Sciences
453 papers in training set
Top 5%
2.2%
10
Molecular Cancer Therapeutics
33 papers in training set
Top 0.2%
2.1%
11
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
1.9%
12
BMC Cancer
52 papers in training set
Top 1%
1.7%
13
Journal of Leukocyte Biology
40 papers in training set
Top 0.2%
1.7%
14
JCI Insight
241 papers in training set
Top 3%
1.7%
15
Cell Communication and Signaling
35 papers in training set
Top 0.5%
1.4%
16
The Journal of Immunology
146 papers in training set
Top 1%
1.4%
17
Cells
232 papers in training set
Top 4%
1.3%
18
Cancer Research Communications
46 papers in training set
Top 0.7%
1.1%
19
Molecular Oncology
50 papers in training set
Top 0.6%
1.1%
20
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.0%
21
Mucosal Immunology
42 papers in training set
Top 0.2%
1.0%
22
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.7%
0.9%
23
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.6%
0.8%
24
The Journal of Pathology
22 papers in training set
Top 0.4%
0.8%
25
npj Precision Oncology
48 papers in training set
Top 1%
0.8%
26
European Journal of Immunology
57 papers in training set
Top 0.5%
0.8%
27
Experimental & Molecular Medicine
14 papers in training set
Top 0.2%
0.7%
28
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.7%
29
Cell Reports Medicine
140 papers in training set
Top 8%
0.7%
30
International Journal of Cancer
42 papers in training set
Top 1%
0.7%